A mixture of lactosylceramide and sialogangliosides
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Lactosylceramide and Ganglioside GM3 and GD3 Mixture

Item No. 29361

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formulation
A 500 µg/ml solution in chloroform:methanol:water (2:1:0.1)
Solubility(Learn about Variance in Solubility)
Chloroform:Methanol:Water (2:1:0.1): soluble
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 ml

    $303

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Lactosylceramides (LacCers) are endogenous bioactive membrane sphingolipids. They have a role in phagocytosis, chemotaxis, and cell signaling.1 LacCer levels are correlated with insulin resistance, obesity, and hyperglycemia in diabetic mice and LacCers enhance neurodegeneration in a mouse model of multiple sclerosis.2,3 Sialogangliosides are membrane sphingolipids composed of sialic acid and oligosaccharide moieties with roles in cell proliferation, differentiation, adhesion, neuronal plasticity, intra- and intercellular signaling, and neurogenesis.4,5,6 They accumulate in a variety of lysosomal storage disorders including Sandhoff, Tay-Sachs, and Niemann-Pick diseases.7,8 Lactosylceramide and Ganglioside GM3 and GD3 Mixture contains lactosylceramide (LacCer), ganglioside GM3, and ganglioside GD3. It is intended for use as a reference standard for the detection of LacCer, ganglioside GM3, and ganglioside GD3 in various sample types by TLC or LC-MS. This mixture is supplied in an amber ampule in which the headspace has been purged with argon to prevent lipid oxidation. [Matreya, LLC. Catalog No. 1510]

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Iwabuchi, K., Nakayama, H., Oizumi, A., et al. Role of ceramide from glycosphingolipids and its metabolites in immunological and inflammatory responses in humans. Mediators Inflamm. 2015, 120748 (2015).

    2. Subathra, M., Korrapati, M., Howell, L.A., et al. Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells. Am. J. Physiol. Renal Physiol. 309(3), F204-F215 (2015).

    3. Mayo, L., Trauger, S.A., Blain, M., et al. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat. Med. 20(10), 1147-1156 (2014).

    4. Kolter, T. Ganglioside biochemistry. ISRN Biochem. 506160 (2012).

    5. Mukherjee, P., Faber, A.C., Shelton, L.M., et al. Thematic review series: Sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a. J. Lipid Res. 49(5), 929-938 (2008).

    6. Wang, J., Cheng, A., Wakade, C., et al. Ganglioside GD3 is required for neurogenesis and long-term maintenance of neural stem cells in the postnatal mouse brain. J. Neurosci. 34(41), 13790-13800 (2014).

    7. Baek, R.C., Martin, D.R., Cox, N.R., et al. Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Lipids 44(3), 197-205 (2009).

    8. Walkley, S.U. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin. Cell Dev. Biol. 15(4), 433-444 (2004).